BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Startups

  BMS, Bain Birth Biotech for Autoimmune Disorders

  BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.

  July 29, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  RFK Jr. Looks to Overhaul ‘Broken’ Vaccine Injury Compensation Program

  In a post on X, Health Secretary Robert F. Kennedy Jr. alleged that the Vaccine Injury Compensation Program has “devolved into a morass of inefficiency, favoritism, and outright corruption.”

  July 29, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Tariffs

  15% Tariffs Come to Pharma in New EU Trade Deal

  While some analysts forecast the tariffs could mean billions in additional industry expenditure, others expect the overall impact to be “manageable.”

  July 29, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  Senate Democrats Investigating HHS Secretary Kennedy’s ACIP Firing

  Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.

  July 29, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  C-suite

  Novo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%

  In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.

  July 29, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Earnings

  Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D

  CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savings to be reinvested to support up to 20 new product launches.

  July 29, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D

  Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.

  July 29, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  FDA

  Prasad Out at CBER Following Sarepta Rollercoaster and Conservative Criticism

  The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, where he had been the head of the Center for Biologics Evaluation and Research for less than three months.

  July 29, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• Press Releases

  Pahr Therapeutics Raises $14 Million Seed Financing to Pursue Innovative Treatments for Pulmonary Arterial Hypertension

  July 29, 2025

   · 

  1 min read
• Press Releases

  Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

  July 29, 2025

   · 

  2 min read